MPM Oncology Impact Management »

Replimune Group shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Replimune Group (REPL) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Replimune Group

Tip: Access up to 7 years of quarterly data

All positions including Replimune Group held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Replimune Group by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-06-30 $9.1M 984k 9.29
2025-03-31 $9.6M 987k 9.75
2024-12-31 $12M 950k 12.11

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Replimune Group

Baker Bros. Advisors
Rtw Investments
BlackRock
Fcpm Iii Services B.v.
Point72 Asset Management
Ally Bridge Group
Susquehanna International
Vanguard Group
Tang Capital Management
State Street Corporation
Braidwell
Balyasny Asset Management
Readystate Asset Management
Millennium Management
Geode Capital Management

View all funds holding Replimune Group